BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychiatric disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops dyslexia adjunctive recovery training software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions, as well as bone trauma and pain cognitive impairment digital therapeutics product. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.
Frequently asked questions
What sector does BrainAurora Med Tech Ltd (6681) operate in?
BrainAurora Med Tech Ltd belongs to the Other sector and operates in the Health Information Services industry.
What is BrainAurora Med Tech Ltd (6681) current stock price?
As of the latest data, BrainAurora Med Tech Ltd stock price is HK$1.07, with a previous close of HK$0.94. BrainAurora Med Tech Ltd gained HK$0.13 in the last trading session, representing a 13.3% increase.
What is BrainAurora Med Tech Ltd (6681) current market capitalization?
BrainAurora Med Tech Ltd market cap is approximately 1.38 billion.
What is BrainAurora Med Tech Ltd (6681) EBITDA?
BrainAurora Med Tech Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -52.62 million.
Does BrainAurora Med Tech Ltd (6681) pay dividends?
No. BrainAurora Med Tech Ltd does not pay a dividend.
What is BrainAurora Med Tech Ltd (6681) beta (volatility) score?
BrainAurora Med Tech Ltd has a beta of -0.263, indicating lower volatility than the overall market.